Dopamine (DA) is an important catecholamine neurotransmitter in the mammalian central nervous system that influences several physiological functions. The impact of DA levels within the human body significantly affects the body functions. Maintaining DA level is essential and the electrochemical detection methods are often used to detect the DA level to regulate the body function. In this review, graphene (functionalized graphene and N-doped graphene) and its composites (metal, metal oxide, polymer, carbonaceous materials, clay, zeolite, and metal-organic framework based graphene composites) modified electrodes with their improved sensing performance towards DA along with several interfering species are described. Further, recent developments on the fabrication of various graphene based composite modified electrodes are also presented. Some important strategies to improve the selectivity and sensitivity towards DA with graphene based composite modified electrodes are also described.
This review (with 110 refs.) gives an overview on the progress that has been made in the past few years on the use of gold nanoparticles (AuNPs) for use in sensors and analytical tools for the determination of dopamine (DA). Both AuNPs and their composites with other organic and inorganic materials including noble metals are treated. Following an overview on the clinical significance of DA, we discuss the various analytical methods that are (a) electrochemiluminescence (ECL); (b) surface enhanced Raman scattering (SERS); (c) colorimetric probing and visual detection; and (d) the large class of electrochemical sensors. Subsections cover sensors based on plain AuNPs, bimetallic NPs, AuNP-metal@metal oxide nanocomposites, AuNP nanocomposites with organic polymers, AuNP nanocomposites with carbon nanotubes or with graphene, and finally sensors based on ternary materials containing AuNPs. The review ends with a conclusion on current challenges of sensors for DA and an outlook on future trends.
A one-step method for the synthesis of zinc oxide/reduced graphene oxide (ZnO/rGO) nanocomposites by a hydrothermal technique is reported. This simple method involves a hydrothermal treatment of a solution comprising graphene oxide (GO), Zn(CH3COO)2.2H2O, NaOH and NH3.H2O. The concentration of GO as a starting material plays an important role in the density distribution of ZnO nanorods on the rGO sheets and on the percentage of the formation of ZnO/rGO nanocomposites. The resulting rod-like ZnO nanoparticles formed on the rGO sheets, in high density, has a potential in the gas sensing application.
A simple single-stage approach, based on the hydrothermal technique, has been introduced to synthesize reduced graphene oxide/titanium dioxide nanocomposites. The titanium dioxide nanoparticles are formed at the same time as the graphene oxide is reduced to graphene. The triethanolamine used in the process has two roles. It acts as a reducing agent for the graphene oxide as well as a capping agent, allowing the formation of titanium dioxide nanoparticles with a narrow size distribution (∼20 nm). Transmission electron micrographs show that the nanoparticles are uniformly distributed on the reduced graphene oxide nanosheet. Thermogravimetric analysis shows the nanocomposites have an enhanced thermal stability over the original components. The potential applications for this technology were demonstrated by the use of a reduced graphene oxide/titanium dioxide nanocomposite-modified glassy carbon electrode, which enhanced the electrochemical performance compared to a conventional glassy carbon electrode when interacting with mercury(II) ions in potassium chloride electrolyte.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.